We are here to help! If you can answer ‘yes’ to any of the following, we can provide educational information to your Urologist.
Are you:
Newly diagnosed with prostate cancer?
Currently on active surveillance?
If you are interested and would like us to reach out to your provider, please fill out their information below
You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.
Contact Information
Prolaris is an advanced genetic test that combines tools like Gleason score and PSA with a personalized tumor score to determine how aggressive your prostate cancer is. Prolaris helps you and your doctor decide the best treatment option based on your specific cancer.
Prostate cancer is personal and treatment should be too. Prolaris is for any newly diagnosed man with prostate cancer and helps patients and providers answer pressing clinical questions like:
Get our free testing guide
65%
In two clinical utility studies, Prolaris results lead to change in management in up to 65% of patients.1,2,3
2x
The Prolaris score is 2x more prognostic than PSA and Gleason score combined4
$0
97% of patients pay $0 out of pocket
Watch how Richard and his doctor worked together to decide on the best treatment option for him based on his Prolaris results.
You may have inherited more than just your eye color from your parents
MyRisk is a genetic test that identifies hereditary (germline) mutations to determine if you have an inherited form of cancer. MyRisk helps high-risk or metastatic prostate cancer patients qualify for new, personalized treatments – like targeted medications, clinical trials or if you have an elevated risk of developing a secondary cancer.
Request test kit
Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to determine if a patient can safely watch their cancer in favor of active surveillance or if they should pursue treatment.
MyRisk is a germline test that offers a multi-gene panel to determine a patient’s risk of developing secondary cancers, as well as their children’s risk for the same germline mutations. MyRisk can also qualify patients for newer, personalized treatments such as targeted therapies and immunotherapy.
A somatic test that assesses 500+ genes, as well as key biomarkers like MSI, TMB and PD-L1, to determine if a patient’s tumor may be appropriate for novel therapies or clinical trials.
Contact our trusted advisors for personalized support.
Learn how genetic testing can provide better answers for the best prostate cancer treatment for you in our FREE Patient Testing Guide.